Nicotine therapeutic benefits: Difference between revisions
Jump to navigation
Jump to search
(Fixed type) |
(Added content to Down's Syndrome) |
||
| Line 521: | Line 521: | ||
==Down's Syndrome== <!--T:114--> | ==Down's Syndrome== <!--T:114--> | ||
===2001: [https://link.springer.com/chapter/10.1007/978-3-7091-6262-0_19 Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome]=== | |||
*To explore the potential for cognitive enhancement utilizing nicotinic stimulation, 8 patients with Down syndrome (aged 18.5–31 years) received placebo and a single dose of transdermal nicotine (5mg patch) over 2h in a single-blind, within-subjects repeated measures design. | |||
*Neuropsychological tests exhibited improvements in digit symbol performance subtest in 4 of 8 subjects and 7 of 8 subjects in the Frankfurt Attention Inventory. These results suggest that stimulating central nicotinic receptors might have an acute cognitive benefit in young adult Down syndrome subjects. | |||
*Citation: Bernert G., Sustrova M., Sovcikova E., Seidl R., Lubec G. (2001) Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome. In: Lubec G. (eds) Protein Expression in Down Syndrome Brain. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6262-0_19 | |||